JAK2 and acute myeloid leukemia: Specifically, AML-MSCs secrete a substantial quantity of IL-6 and induce epithelial-mesenchymal transition (EMT)-like transformation in AML cells through the Jak2/Stat3 signaling pathway, potentially contributing to chemotherapy resistance (179).